Genxone (WAR:GX1) Total Equity: zł7.89 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WAR:GX1 Genxone SA WAR:GX1
66 GF Score
Price zł5.68
GF Value zł6.51
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Genxone Total Equity?

Genxone WAR:GX1 -0.35% 66 Total Equity is zł7.89 Mil as of Mar. 2026. GuruFocus rates WAR:GX1 with a GF Score™ of 66/100 and a GF Value™ of zł6.51 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Genxone's total equity for the quarter that ended in Mar. 2026 was zł7.89 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Genxone Total Equity Historical Data

* Premium members only.

The historical data trend for Genxone's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genxone Total Equity Chart

Genxone Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial 21.50 18.69 14.97 11.05 8.41

Genxone Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.32 9.75 9.10 8.41 7.89
WAR:GX1
66GF Score
Genxone SA WAR:GX1
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genxone Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Genxone's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=8.963-0.553
=8.41

Genxone's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=8.345-0.452
=7.89

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of zł7.89 Mil mean?
Genxone (WAR:GX1) has a Total Equity of zł7.89 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Genxone and its competitors.
Is Genxone's Total Equity too high?
Genxone's current Total Equity is zł7.89 Mil. Overall, Genxone has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genxone's Total Equity compare to VRTX and REGN?
Genxone's Total Equity of zł7.89 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Genxone and its competitors. Genxone's current Total Equity is zł7.89 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genxone stock overvalued right now?
Based on GuruFocus' analysis, Genxone (WAR:GX1) is currently considered Modestly Undervalued. The stock's GF Value™ is zł6.51, compared to a current price of zł5.68 — trading 12.7% below its estimated fair value. The current Total Equity is zł7.89 Mil. Genxone's overall GF Score™ is 66/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Genxone (WAR:GX1), the current Total Equity is zł7.89 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genxone (WAR:GX1) Overvalued in 2026?

Based on GuruFocus' analysis, Genxone stock appears to be undervalued. The current stock price of zł5.68 is trading 12.7% below its estimated GF Value™ of zł6.51. GuruFocus considers Genxone to be Modestly Undervalued.

Key valuation signals for WAR:GX1:

  • Total Equity: zł7.89 Mil
  • GF Value™: zł6.51 vs. price of zł5.68 (12.7% below fair value)
  • GF Score™: 66/100 with 2 warning signs

No single metric tells the full story. See the WAR:GX1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Genxone Business Description

Address Kobaltowa Street 6, Zlotniki, POL, 62002
Genxone SA is a biotechnology company that applies nanopore sequencing technology (third-generation of NGS) to many areas of science and business, including genetic diagnostics and the food industry. It specializes in developing new products and solutions based on the latest technologies of nucleic acid sequencing. The company's services include NANOPORE SEQUENCING that includes Whole Genome Sequencing, Bespoke Analysis, Metagenome Sequencing, Bioinformatic Analysis, 16S and/or ITS Gene Sequencing, and RNA Sequencing; and DIAGNOSTIC TESTS that includes Gastrointestinal Infections Panel, Respiratory Infections Panel, Urogenital Infection Panel, and Nervous System Infection Panel.
66GF Score

Get the complete analysis for WAR:GX1

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł5.68
Price
zł6.51
GF Value